Online Dermatologist > Blog > Charles SLBG Foundation Skin Cancer Screening Report

Charles SLBG Foundation Skin Cancer Screening Report

by | Apr 6, 2023 | Blog, Research, Skin Cancer

Main Author: Madushi Jayawickrama | Faculty of Medicine, University of Ruhuna

Introduction

 

The online skin cancer screening project launched by First Derm and The Charles SLBG Foundation aims to provide a free assessment service and help catch skin cancer lesions early, especially in young people. This service is free, fast, and confidential. Users are advised to see a dermatologist when necessary; for others, reassurance is provided and unnecessary doctor visits are prevented.

This literature review is intended to summarize current trends in utilizing teledermatology for skin cancer screening and to highlight the requirement and importance of the First Derm Free Online Skin Cancer Screening Project specifically.

Skin cancers can be identified at early stages because of the outward manifestation of a visible skin lesion. Research evidence shows that the most common type of cancer seen in the United Kingdom is Keratinocyte Cancer (KC), which includes the two main non-melanoma skin malignancies: basal cell carcinoma and cutaneous squamous cell carcinoma.1 One in every five people in the United Kingdom has had non-melanocytic skin cancer at some point in their lives.1 Therefore, the identification and treatment of skin malignancies are essential. Also, according to national cancer registration data analysis, the mortality rate due to melanoma in the United Kingdom is increasing.2 This may depict increasing incidence with simultaneous stable survival of the patients, therefore it implies a recent improvement in survival/prognosis. 2

A diagram showing the classification of skin cancer based on the type of cells affected. The diagram has three main branches: basal cell carcinoma, squamous cell carcinoma, and melanoma. Basal cell carcinoma and squamous cell carcinoma are classified as non-melanoma skin cancers and originate from the epidermis, the outermost layer of the skin. Melanoma is a type of skin cancer that develops from melanocytes, the pigment-producing cells in the epidermis. The diagram also shows the relative frequency and mortality rates of each type of skin cancer, with basal cell carcinoma being the most common and least deadly, and melanoma being the least common and most deadly

Figure 1: Classification of skin cancer

 

 

Methods

 

A literature search was conducted through PubMed with the aim of identifying patterns and current trends in online skin cancer screening platforms. Table 1 summarizes the search terms used, and the number of results that were obtained.

Summary of PubMed search results

Table 1: Summary of PubMed search results

 

 

As shown in Figure 2, the usage of teledermatology tools for the diagnosis of melanoma has increased progressively from 2012 to 2021. The survival/prognosis improvement may correlate to the increased usage of online platforms for skin cancer screening, which helps in early diagnosis.

bar chart of teledermatology in diagnosis of melanoma

Figure 2: Usage of Teledermatology tools for the diagnosis of melanoma

 

Similar platforms

 

Several existing initiatives provide skin cancer screening services free of charge, including “Melanoma Monday” and “Euro Melanoma Monday”. Melanoma Monday, initiated in 1985 by the American Academy of Dermatology (AAD) has provided free screening for more than 2.1 million individuals and identified 23 500 suspected melanomas to date.3 These screening days are in the month of May and also increase public awareness of skin cancers, which helps in directing patients to dermatologists for early diagnosis. However, in these physical screening projects, accessibility is not dispersed equally to everyone.

Teledermatology has taken an increasingly prominent role in the health care system as it gained the interest of the scientific community in recent years.4 Its potential to revolutionize the delivery of dermatology services has been depicted in several studies. Especially the efficacy of teledermatology as a triage system is highlighted.4

There have been a number of teledermatology applications tested in skin cancer screening. The majority of these platforms used the submission of images of the lesions for visual examination, which were compared with a virtual database. Several studies have been conducted to compare the outcomes of face-to-face diagnosis and diagnosis made using teledermatology. Tan et al. present promising results with only a 12.3% disparity between the outcomes of the two modes used.5 Massone et al. show similar results in the study conducted to assess the feasibility of teledermatology using mobile phone photographs of pigmented skin lesions.6 89% accuracy is reported in teleconsulting. However, only 18 patients were involved in this latter study.

An observational cross-sectional study conducted by the Center for Telemedicine and Telehealth of State Secretariat of Health of Santa Catarina to compare the diagnosis of skin cancer in teledermatology and primary care reports low compatibility between the two.7 And according to the current literature, the number of online skin cancer screening platforms that are freely accessible is extremely low. Börve el al proved that teledermoscopy was an excellent way of referring the right patient at the right time from primary care to a dermatology center, saving time, money and patient burden of coming back for a second visit8. They identified 35 malignant melanomas; instead of waiting an average 35 days to come in with a melanoma using the traditional referral system, all suspected melanoma patients were seen within 9 days and 84% had surgery on the first visit. In the study they also showed that the depth of malignant melanoma (Breslow score) was considerably thinner compared to the traditional referrals, 1mm vs 2mm, which is considerable considering the survival rate.

 

First Derm platform

 

First Derm offers online dermatology and has been created from scientific research8 and is available as an app or via the web. In regards to this SLBG foundation project, it has been offered for free, mainly targeting young people living in the United Kingdom. Through the First Derm website, the users can submit a close-up photograph (10 cm/ 4 inches away) and an overview photograph (30 cm/ 12 inches away) of the lesion. Then they are allowed to describe the lesion in detail, with information such as location, color, size, and duration of it. Finally, the other details such as gender, age, and country. Based on these details, a probable diagnosis and guidance for management and treatment are provided to the patient within 24 hours. Patients can either view the reply through the website, app, or email. Privacy and confidentiality are assured for all users.

Unlike fully automated systems where the submitted data is analyzed by an algorithm that has been trained on a database, the First Derm platform involves a panel of board-certified dermatologists who will provide their expert opinions after assessing the data and images of the submitted skin lesions. Therefore, it is safe and reliable. This online platform makes healthcare more accessible worldwide because anyone with internet access and a smartphone can use this service. It provides people the opportunity to connect with experts from the comfort of their own homes. This platform provides solutions for unequally distributed medical experts in different geographical areas and economic burdens that are restricting the efficacy of the conventional face-to-face screening system.

Furthermore, it has an extremely user-friendly interface with clear instructions. People can access the landing page through the First Derm website. In addition to skin cancer screening, this platform offers patient education regarding various skin pathologies through the First Derm website. Multiple images and relevant details explained in a simple understandable manner helps the general public improve their knowledge of the conditions they might have.

 

Acquiring users

 

We used Google ads targeted to UK users for $2333 during the six months period. Targeting 25 to 65 years old and both genders. With a broad set of keywords all regarding checking your moles for free.

google ads campaign age distribution

Distribution of campaign reach within the age group 25 – 64

google ads keywords used

Keywords used in the Google ads campaign

Ad spent within 6 months period

 

Screening results

 

Aggregate data

 

  • A total of 2071 responses were received during 6 months: From June 2022 to November 2022.
  • Cases/day: 11.32
  • Number of different conditions identified: 83

 

Usage of the First Derm free skin cancer screening platform by different age groups

 

  • The average age of users: 29 years old
  • Youngest user: 4 years old       
  • Oldest user: 66 years old

An image of a bar chart showing the usage of the First Derm free skin cancer screening platform by different age groups. The vertical axis represents the number of users and the horizontal axis represents the age group. The chart has seven bars of different colors, one for each age group. The highest bar is for the 20 to 29 age group, with 1061 users. The second highest bar is for the 30 to 39 age group, with 599 users. The lowest bars are for the 60 to 69 age group and the under 10 age group, with 26 and 29 users respectively

Usage of First Derm skin cancer screening platform by different age groups

An image of a table showing the usage of the First Derm free skin cancer screening platform by different age groups. The table has three columns: age group, number of users, and percentage out of total. The data shows that the majority of users are in the 20 to 29 age group, followed by the 30 to 39 age group. The least number of users are in the 60 to 69 age group and the under 10 age group.

First Derm skin cancer screening platform usage by age groups, respective no of users, and their percentage

Gender analysis of clients of the First Derm free skin cancer screening platform

 

  • The majority of users were females.

A pie chart showing the percentage of male and female clients who used First Derm platform for skin cancer screening in 2022. The chart has two slices, one for each gender, with the labels “Male” and “Female” next to them. The female slice is light blue and covers 71% of the pie, while the male slice is blue and covers 29% of the pie

A pie chart showing the gender distribution of First Derm’s skin cancer screening users

 

Skin malignancies and the 10 most common skin conditions identified

a bar chart showing the skin malignancies and the 10 most common skin conditions identified through the First Derm skin cancer screening platform. The vertical axis represents the count of cases and the horizontal axis represents the disease. The chart has 14 bars of different colors, one for each disease. The bars are arranged from left to right in descending order of count. The highest bar is for dermal nevus, with 606 cases. The second highest bar is for atypical nevus, with 269 cases. The lowest bars are for Bowen’s disease and squamous cell carcinoma, with 8 and 0 cases respectively. The chart also shows the bars for basal cell carcinoma and malignant melanoma, which are two types of skin cancer

Skin malignancies and the 10 most common skin conditions identified

An image of a table showing the skin malignancies and the 10 most common skin conditions identified through the First Derm skin cancer screening platform. The table has three columns: disease, count, and percentage. The data shows that the most common condition is dermal nevus, with 606 cases and 29.3% of the total. The second most common condition is atypical nevus, with 269 cases and 12.9% of the total. The least common conditions are Bowen’s disease and squamous cell carcinoma, with 8 and 0 cases respectively. The table also shows the number and percentage of cases of basal cell carcinoma and malignant melanoma, which are two types of skin cancer.

 

Differential count of identified skin malignancies

An image of a pie chart showing the differential count of identified skin malignancies through the First Derm skin cancer screening platform. The chart has three segments of different colors, one for each type of skin cancer. The chart has two main divisions marked as basal cell carcinoma and malignant melanoma. The largest segment is for basal cell carcinoma, with 51% of the total. The second largest segment is for malignant melanoma, with 38% of the total. The smallest segment is for squamous cell carcinoma, with 0% of the total. The other segment is for Bowen’s disease, with 11% of the total.

Differential count of identified skin malignancies

 

 

 

Recommendations given

  • Potentially 28 lives were saved (malignant melanomas).
  • 802 unnecessary consultations were prevented.

A table showing the instructions given during an online skin cancer screening via first derm and their corresponding count and percentage. The table has three columns: instruction, count, and percentage. The table has nine rows, including the header row. The most frequent instruction is to verify a benign diagnosis with a dermatoscope, followed by seeing a dermatologist only if suggested therapies do not improve the symptoms, and seeing a dermatologist if the appearance changes. The least frequent instructions are to see a dermatologist if symptoms persist and to acknowledge that there is no cure.

Table showing the instructions given during the online skin cancer screening via first derm and their corresponding count and percentage

A pie chart showing the percentage of instructions given during an online skin cancer screening via first derm. The pie chart has nine slices, each labeled with the instruction and the percentage. The largest slice is for verifying a benign diagnosis with a dermatoscope, which accounts for 47.5% of the cases. The smallest slices are for seeing a dermatologist if symptoms persist and acknowledging that there is no cure, which each account for 0.4% of the cases.

 

 

Skin conditions with malignant melanocytes and benign melanocytes

A pie chart that shows the proportion of skin conditions with malignant or benign melanocytes. The pie chart has two slices: one for malignant melanocytes and one for benign melanocytes. The slice for malignant melanocytes occupies a very small fraction of the pie chart, while the slice for benign melanocytes occupies almost the entire pie chart. The pie chart is based on the data acquired through First Derm, a skin cancer screening platform. The pie chart illustrates that benign melanocyte conditions are much more prevalent than malignant ones, with 1317 cases versus 74 cases

Skin conditions with malignant melanocytes and benign melanocytes

 

The table is based on the data acquired through First Derm, a skin cancer screening platform. Some examples of the subtypes are basal cell carcinoma, malignant melanoma, Bowen’s disease, dermal nevus, atypical nevus, seborrhoeic keratosis, etc. The table shows that benign melanocyte conditions are much more common than malignant ones, with 1317 cases versus 74 cases

 

  • 802 unnecessary consultations were prevented.
  • Users of the First Derm Free Online Skin Cancer Screening platform are typically males in their late 20s from the UK.
  • This platform has had the potential to save lives, because of the early detection of malignant melanoma.

 

Limitations in data review

Unclear images and some other problems lead to the inability to arrive at a certain answer on the skin concern, in which case multiple differential answers were listed.

 

Conclusion

According to the literature, skin malignancies are a major ongoing problem with high prevalence, high mortality, and morbidity rates. Early diagnosis is extremely important for a favorable prognosis. Therefore new methods are necessary for early diagnosis and to direct patients with suspicious skin lesions to dermatologists fast.

The First Derm online skin cancer screening platform fulfills these requirements and identified 28 potential malignant melanomas. Eighty percent of the users were between 20-39 years old. As a triage tool for the early detection of skin cancers, this platform has great value. The literature contains both successful and unsuccessful attempts at utilizing teledermatology as a diagnostic and screening tool.

 

References

 

  1. Kwiatkowska, M., Ahmed, S., Ardern-Jones, M., Bhatti, L. A., Bleiker, T. O., Gavin, A., Hussain, S., Huws, D. W., Irvine, L., Langan, S. M., Millington, G. W. M., Mitchell, H., Murphy, R., Paley, L., Proby, C. M., Thomson, C. S., Thomas, R., Turner, C., Vernon, S., & Venables, Z. C. (2021). An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013–2018. Skin Health and Disease, 1(4). https://doi.org/10.1002/SKI2.61
  2. Memon, A., Bannister, P., Rogers, I., Sundin, J., Al-Ayadhy, B., James, P. W., & McNally, R. J. Q. (2021). Changing epidemiology and age-specific incidence of cutaneous malignant melanoma in England: An analysis of the national cancer registration data by age, gender, and anatomical site, 1981–2018. The Lancet Regional Health – Europe, 2. https://doi.org/10.1016/J.LANEPE.2021.100024
  3. Boulos, S., Fiala, K., & Butler, D. F. (2012). Free skin cancer screening provides access to care. Journal of the American Academy of Dermatology, 67(4), 787–788. https://doi.org/10.1016/J.JAAD.2012.02.027
  4. Fabbrocini, G., de Vita, V., Pastore, F., D’Arco, V., Mazzella, C., Annunziata, M. C., Cacciapuoti, S., Mauriello, M. C., & Monfrecola, A. (2011). Teledermatology: from prevention to diagnosis of nonmelanoma and melanoma skin cancer. International Journal of Telemedicine and Applications, 2011. https://doi.org/10.1155/2011/125762
  5. E. Tan, A. Yung, M. Jameson, A. Oakley, and M. Rademaker,“Successful triage of patients referred to a skin lesion clinicusing teledermoscopy (IMAGE IT trial),”British Journal ofDermatology, vol. 162, no. 4, pp. 803–811, 2010.
  6. C. Massone, R. Hofmann-Wellenhof, V. Ahlgrimm-Siess, G.Gabler, C. Ebner, and H. P. Soyer, “Melanoma screening with cellular phones,”PloS one, vol. 2, no. 5, p. e483, 2007.
  7. Piccoli, M. F., Amorim, B. D. B., Wagner, H. M., & Nunes, D. H. (2015). Teledermatology protocol for screening of skin cancer. Anais Brasileiros de Dermatologia, 90(2), 202–210. https://doi.org/10.1590/ABD1806-4841.20153
  8. Börve A, Dahlén Gyllencreutz J, Terstappen K, Johansson Backman E, Aldenbratt A, Danielsson M, Gillstedt M, Sandberg C, Paoli J. “Smartphone Teledermoscopy Referrals: A Novel Process for Improved Triage of Skin Cancer Patients.” Acta Derm Venereol (2014). Web.

Over 15,000+ Readers

Get fresh content from First Derm

Ask a Dermatologist Now

Anonymous, fast and secure!

logo
1 (415) 234-4124
Get Checked